Streetinsider.com's Hot Lunchtime Reads 11/8: (DEPO) (VRX) (VIPS) (PGNX)

November 8, 2016 12:20 PM EST

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

The following is a list of notable articles to help get you through the lunch hour:
  • S&P Affirms Rating on Valeant Pharma (VRX) Amid Weak Q3 Report, Cut Outlook -> Read this!

  • Street Watchdog Research Sees 'Accounting Irregularities' at Vipshop (VIPS) -> Read this!

  • Aegis Affirms Progenics Pharma (PGNX) at 'Buy'; Solid Relistor Results Fuel Q3 Revenue Gains (VRX) -> Read this!

  • Roth Capital Affirms Stemline Therapeutics (STML) at 'Buy'; Strong Cash Position Noted Ahead of ASH -> Read this!

  • Leerink Keeps Depomed (DEPO) at 'Outperform'; Disappointing Q3 Steps-up Pressure to Sell -> Read this!



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Roth Capital, Standard & Poor's

Add Your Comment